Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solanezumab - Eli Lilly

Drug Profile

Solanezumab - Eli Lilly

Alternative Names: Anti-amyloid-beta monoclonal antibody - Eli Lilly; Anti-Aβ monoclonal antibody - Eli Lilly; LY-2062430

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 May 2018 Eli Lilly suspends patient enrolment in the phase II/III DIAN-TU trial for Alzheimer's disease (Early-stage disease) in USA, United Kingdom, Spain and Italy to explore options to improve the benefit / risk for these patients (PO)
  • 16 Jul 2017 Pharmacodynamics data from the phase III EXPEDITION3 trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top